BioCentury | Feb 16, 2017
Financial News

SOM Biotech completes venture financing

...€2 million ($2.1 million) in a financing round from angel investors. SOM Biotech S.L. , Barcelona, Spain Alicia Parker SOM Biotech S.L....
BioCentury | Dec 16, 2016
Company News

SOM Biotech deal

...to treat amyloidosis. SOM declined to disclose additional details. SOM Biotech S.L. , Barcelona, Spain Business: Endocrine/Metabolic Alicia Parker SOM0226 Tolcapone SOM Biotech S.L. Transthyretin...
BioCentury | Dec 7, 2015
Regulation

Action in amyloidosis

...NYSE:GSK) ISIS-TTRRx (GSK2998728) TTR antisense inhibitor Ph II/III for FAP mNIS+7 and Norfolk QOL questionnaire SOM Biotech S.L....
BioCentury | Nov 9, 2015
Clinical News

Tolcapone: Phase IIa data

...reported. Data were presented at the European Congress on Hereditary ATTR amyloidosis meeting in Paris. SOM Biotech S.L....
BioCentury | Nov 4, 2015
Clinical News

Alnylam, SOM Biotech, Isis update TTR programs

...included results from clinical studies of transthyretin amyloid disease therapies from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), SOM Biotech S.L....
...using the GalNAc-conjugate delivery platform. Data in an abstract from a Phase IIa study of SOM Biotech's...
Items per page:
1 - 5 of 5
BioCentury | Feb 16, 2017
Financial News

SOM Biotech completes venture financing

...€2 million ($2.1 million) in a financing round from angel investors. SOM Biotech S.L. , Barcelona, Spain Alicia Parker SOM Biotech S.L....
BioCentury | Dec 16, 2016
Company News

SOM Biotech deal

...to treat amyloidosis. SOM declined to disclose additional details. SOM Biotech S.L. , Barcelona, Spain Business: Endocrine/Metabolic Alicia Parker SOM0226 Tolcapone SOM Biotech S.L. Transthyretin...
BioCentury | Dec 7, 2015
Regulation

Action in amyloidosis

...NYSE:GSK) ISIS-TTRRx (GSK2998728) TTR antisense inhibitor Ph II/III for FAP mNIS+7 and Norfolk QOL questionnaire SOM Biotech S.L....
BioCentury | Nov 9, 2015
Clinical News

Tolcapone: Phase IIa data

...reported. Data were presented at the European Congress on Hereditary ATTR amyloidosis meeting in Paris. SOM Biotech S.L....
BioCentury | Nov 4, 2015
Clinical News

Alnylam, SOM Biotech, Isis update TTR programs

...included results from clinical studies of transthyretin amyloid disease therapies from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), SOM Biotech S.L....
...using the GalNAc-conjugate delivery platform. Data in an abstract from a Phase IIa study of SOM Biotech's...
Items per page:
1 - 5 of 5